These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15380271)

  • 1. Susceptibility pattern of extended-spectrum beta-lactamase producing bacteria isolated from inpatients to five antimicrobial drugs in a community hospital in Northern Israel.
    Colodner R; Raz R; Chazan B; Sakran W
    Int J Antimicrob Agents; 2004 Oct; 24(4):409-10. PubMed ID: 15380271
    [No Abstract]   [Full Text] [Related]  

  • 2. First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel.
    Colodner R; Samra Z; Keller N; Sprecher H; Block C; Peled N; Lazarovitch T; Bardenstein R; Schwartz-Harari O; Carmeli Y;
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):201-5. PubMed ID: 17258084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis.
    Paterson DL; Singh N; Gayowski T; Marino IR
    Clin Infect Dis; 1999 Mar; 28(3):683-4. PubMed ID: 10194100
    [No Abstract]   [Full Text] [Related]  

  • 4. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefotaxime and ceftazidime-resistant Escherichia coli isolate producing TEM-15 beta-lactamase from a Tunisian hospital.
    Chouchani C; Ben-Achour N; M'charek A; Belhadj O
    C R Biol; 2007 Aug; 330(8):565-70. PubMed ID: 17637436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan.
    Liao CH; Sheng WH; Wang JT; Sun HY; Wang HK; Hsueh PR; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2006 Feb; 39(1):59-66. PubMed ID: 16440125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epidemiological study on extended-spectrum beta-lactamase-producing in clinical isolates and selection of antibacterial drugs in China ].
    Yu YS
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1918-20. PubMed ID: 15631810
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Metan G; Zarakolu P; Cakir B; Hascelik G; Uzun O
    Int J Antimicrob Agents; 2005 Sep; 26(3):254-7. PubMed ID: 16122910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-spectrum-beta-lactamase-producing Escherichia coli strains isolated from farm animals from 1999 to 2002: report from the Japanese Veterinary Antimicrobial Resistance Monitoring Program.
    Kojima A; Ishii Y; Ishihara K; Esaki H; Asai T; Oda C; Tamura Y; Takahashi T; Yamaguchi K
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3533-7. PubMed ID: 16048977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran.
    Mehrgan H; Rahbar M
    Int J Antimicrob Agents; 2008 Feb; 31(2):147-51. PubMed ID: 18060745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract]   [Full Text] [Related]  

  • 13. Integron-mediated ESBL resistance in rare serotypes of Escherichia coli causing infections in an elderly population of Israel.
    Sompolinsky D; Nitzan Y; Tetry S; Wolk M; Vulikh I; Kerrn MB; Sandvang D; Hershkovits G; Katcoff DJ
    J Antimicrob Chemother; 2005 Jan; 55(1):119-22. PubMed ID: 15574469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of OXA-2 group extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli from India.
    Bhattacharjee A; Sen MR; Anupurba S; Prakash P; Nath G
    J Antimicrob Chemother; 2007 Sep; 60(3):703-4. PubMed ID: 17623688
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
    J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enteropathogenic Escherichia coli strains carrying genes encoding the PER-2 and TEM-116 extended-spectrum beta-lactamases isolated from children with diarrhea in Uruguay.
    Vignoli R; Varela G; Mota MI; Cordeiro NF; Power P; Ingold E; Gadea P; Sirok A; Schelotto F; Ayala JA; Gutkind G
    J Clin Microbiol; 2005 Jun; 43(6):2940-3. PubMed ID: 15956426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
    You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
    J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
    J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHV-5 extended-spectrum beta-lactamases in clinical isolates of Escherichia coli in Malaysia.
    Subramaniam G; Palasubramaniam S; Navaratnam P
    Indian J Med Microbiol; 2006 Jul; 24(3):205-7. PubMed ID: 16912441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.